MicroRNAs are poised to radically change the way we care for patients with germ cell tumors (GCTs) across all disease states, from diagnosis to managing chemorefractory disease. miR-371a-3p is a promising candidate biomarker that may precisely individualize GCT treatment paradigms.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Nov 2019|
ASJC Scopus subject areas